PMID- 29588457
OWN - NLM
STAT- MEDLINE
DCOM- 20191007
LR  - 20240314
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 8
IP  - 1
DP  - 2018 Mar 27
TI  - Efficacy and safety of boosted darunavir-based antiretroviral therapy in 
      HIV-1-positive patients: results from a meta-analysis of clinical trials.
PG  - 5288
LID - 10.1038/s41598-018-23375-6 [doi]
LID - 5288
AB  - Darunavir/ritonavir (DRV/r) is a second-generation protease inhibitor used in 
      treatment-naive and -experienced HIV-positive adult patients. To evaluate 
      efficacy and safety in these patient settings, we performed a meta-analysis of 
      randomized controlled trials. We considered eight studies involving 4240 
      antiretroviral treatment (ART)-naive patients and 14 studies involving 2684 
      ART-experienced patients. Regarding efficacy in the ART-naive patients, the 
      virological response rate was not significantly different between DRV/r and the 
      comparator. For the ART-experienced failing patients, the virological response 
      rate was significantly higher with DRV/r than with the comparator (RR 1.45, 95% 
      CI: 1.01-2.08); conversely, no significant differences were found between the 
      treatment-experienced and virologically controlled DRV/r and comparator groups. 
      Regarding safety, the discontinuation rates due to adverse events (AEs) and 
      DRV/r-related serious adverse events (SAEs) did not significantly differ from the 
      rates in the comparator group (RR 0.84, 95% CI: 0.59-1.19 and RR 0.78, 95% CI: 
      0.57-1.05, respectively). Our meta-analysis indicated that DRV/r-based regimens 
      were effective and tolerable for both types of patients, which was consistent 
      with published data.
FAU - Antinori, A
AU  - Antinori A
AD  - HIV/AIDS Department, National Institute for Infectious Diseases "Lazzaro 
      Spallanzani" IRCCS, Roma, Italy.
FAU - Lazzarin, A
AU  - Lazzarin A
AD  - Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, 
      Italy.
FAU - Uglietti, A
AU  - Uglietti A
AD  - Janssen-Cilag SpA, Medical Affairs Department, Infectious Diseases, Cologno 
      Monzese, (MI), Italy.
FAU - Palma, M
AU  - Palma M
AD  - Janssen-Cilag SpA, Medical Affairs Department, Infectious Diseases, Cologno 
      Monzese, (MI), Italy.
FAU - Mancusi, D
AU  - Mancusi D
AD  - Janssen-Cilag SpA, Medical Affairs Department, Infectious Diseases, Cologno 
      Monzese, (MI), Italy. dmancusi@its.jnj.com.
FAU - Termini, R
AU  - Termini R
AD  - Janssen-Cilag SpA, Medical Affairs Department, Infectious Diseases, Cologno 
      Monzese, (MI), Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20180327
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (HIV Protease Inhibitors)
RN  - O3J8G9O825 (Ritonavir)
RN  - YO603Y8113 (Darunavir)
SB  - IM
MH  - Darunavir/adverse effects/*therapeutic use
MH  - HIV Infections/*drug therapy
MH  - HIV Protease Inhibitors/adverse effects/*therapeutic use
MH  - HIV-1/*drug effects
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Ritonavir/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Viral Load/drug effects
PMC - PMC5869729
COIS- Andrea Antinori (A.A.) has received honoraria for consultancies with Gilead 
      Sciences, ViiV Healthcare, Merck Sharp & Dohme, Janssen-Cilag, Abbvie, and 
      Bristol-Myers Squibb and has also received research grants from Gilead Sciences, 
      Bristol-Myers Squibb, Janssen-Cilag, and ViiV Healthcare; Adriano Lazzarin (A.L.) 
      has received fees for advisory board participation and conference talks from BMS, 
      ViiV, Gilead, MSD, Mylan, Abbvie, Janssen Cilag, and Teva; Alessia Uglietti 
      (A.U.), Maria Palma (M.P.), Daniela Mancusi (D.M.) and Roberta Termini (R.T.) are 
      employees of Janssen-Cilag SpA, Italy.
EDAT- 2018/03/29 06:00
MHDA- 2019/10/08 06:00
PMCR- 2018/03/27
CRDT- 2018/03/29 06:00
PHST- 2017/09/25 00:00 [received]
PHST- 2018/03/12 00:00 [accepted]
PHST- 2018/03/29 06:00 [entrez]
PHST- 2018/03/29 06:00 [pubmed]
PHST- 2019/10/08 06:00 [medline]
PHST- 2018/03/27 00:00 [pmc-release]
AID - 10.1038/s41598-018-23375-6 [pii]
AID - 23375 [pii]
AID - 10.1038/s41598-018-23375-6 [doi]
PST - epublish
SO  - Sci Rep. 2018 Mar 27;8(1):5288. doi: 10.1038/s41598-018-23375-6.